Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors at 7 institutions in 2 countries.
Anusmita SahooEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0001-6903-969X
Andrew T JonesEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-3739-2322
Narayanaiah CheedarlaEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0001-6072-4383
Sailaja GangadharaEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0001-8603-628X
Vicky RoyRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-5064-1098
Tiffany M StylesEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-0102-6566
Ayalnesh ShiferawEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Korey L WalterDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0001-6353-5422
LaTonya D WilliamsDepartment of Surgery, Duke University Medical School, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-8064-8533
Xiaoying ShenDepartment of Surgery, Duke University Medical School, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-8387-3952
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, San Diego, CA 92121, USA.ORCID 0000-0002-9695-8138
Wen-Hsin LeeDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, San Diego, CA 92121, USA.ORCID 0000-0001-9445-6671
Samantha BurtonEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Lasanajak YiDepartment of Biochemistry, Emory Glycomics and Molecular Interactions Core (EGMIC), School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-1450-8107
Xuezheng SongDepartment of Biochemistry, Emory Glycomics and Molecular Interactions Core (EGMIC), School of Medicine, Emory University, Atlanta, GA 30322, USA.
Zhaohui S QinDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-1583-146X
Cynthia A DerdeynEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-1220-513X
Andrew B WardDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, San Diego, CA 92121, USA.ORCID 0000-0001-7153-3769
John D ClementsDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 8638, USA.
Raghavan VaradarajanMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, Karnataka 560012, India.ORCID 0000-0002-0823-7577
Georgia D TomarasDepartment of Surgery, Duke University Medical School, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-8076-1931
Pamela A KozlowskiDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-7680-9215
Rama Rao AmaraEmory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-6309-6797
Emory University · USDuke University · USScripps Research Institute · USLouisiana State University Health Sciences Center New Orleans · USRagon Institute of MGH, MIT and Harvard · USJawaharlal Nehru Centre for Advanced Scientific Research · INTulane University · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
B and T Cell Biology of Protection from and Eradication of SIV/SHIV InfectionUM1AI169662 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Eric Hunter · 2022 to 2026
$32.0M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5M
SPF Breeding Colonies at the Yerkes NPRCU24OD011023 · OD · EMORY UNIVERSITY · PI COHEN, JOYCE KIMBERLY · 2012 to 2017
$8.2M
Using DNA/MVA/protein immunization of rhesus macaques to investigate how the background of the HIV-1 envelope and nature of the protein boost shape the genetic and functional antibody landscape.R01AI128837 · NIAID · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD, DERDEYN, CYNTHIA ANN · 2017 to 2021
$5.9M
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV VaccinationR01DE026333 · NIDCR · EMORY UNIVERSITY · PI AMARA, RAMA RAO · 2016 to 2020
$4.7M
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIVR01AI148378 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO · 2019 to 2022
The rising global HIV-1 burden urgently requires vaccines capable of providing heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming with modified vaccinia Ankara (MVA) and boosting with cyclically permuted trimeric gp120 (CycP-gp120) protein, delivered either orally using a needle-free injector or through parenteral injection. We tested protective efficacy of the vaccine against intrarectal challenges with a pathogenic heterologous clade C SHIV infection in rhesus macaques. Both routes of vaccination induced a strong envelope-specific IgG in serum and rectal secretions directed against V1V2 scaffolds from a global panel of viruses with polyfunctional activities. Envelope-specific IgG showed lower fucosylation compared with total IgG at baseline, and most of the vaccine-induced proliferating blood CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques. · full record | OpenQuestion